<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT02247947</url>
  </required_header>
  <id_info>
    <org_study_id>14-053</org_study_id>
    <nct_id>NCT02247947</nct_id>
  </id_info>
  <brief_title>Proteomics to Identify Prognostic Markers After CPR and to Estimate Neurological Outcome</brief_title>
  <official_title>Proteomics to Identify Prognostic Markers After CPR and to Estimate Neurological Outcome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsklinikum Köln</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitätsklinikum Köln</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Proteomics is used to identify prognostic markers after CPR. Additionally neurological&#xD;
      outcome should be estimated by specific protein alterations and affections of pathways.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Proteomics is used to identify prognostic markers after CPR, i.e. altered proteins on a&#xD;
      2G-gel. Additionally neurological outcome should be estimated by specific protein alterations&#xD;
      and affections of pathways.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">November 1, 2020</completion_date>
  <primary_completion_date type="Actual">November 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>death at day 20</measure>
    <time_frame>day 20</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">20</enrollment>
  <condition>Cardiac Arrest</condition>
  <arm_group>
    <arm_group_label>dead</arm_group_label>
    <description>Patients dead until day 20 (primary outcome measure)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>survivors</arm_group_label>
    <description>patients alive after day 20 (primary outcome measure)</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum and urine&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        patients with cardiac arrest of non-trauma origin&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  cardiac arrest&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  trauma&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jochen Hinkelbein, MD</last_name>
    <role>Study Chair</role>
    <affiliation>UK Köln</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital of Cologne</name>
      <address>
        <city>Cologne</city>
        <state>NRW</state>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>September 20, 2014</study_first_submitted>
  <study_first_submitted_qc>September 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2014</study_first_posted>
  <last_update_submitted>November 3, 2020</last_update_submitted>
  <last_update_submitted_qc>November 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitätsklinikum Köln</investigator_affiliation>
    <investigator_full_name>Jochen Hinkelbein</investigator_full_name>
    <investigator_title>Priv.-Doz. Dr. med.</investigator_title>
  </responsible_party>
  <keyword>CPR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Arrest</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT02247947
org study id: 14-053
nct id: NCT02247947
lead sponsor: 
has dmc: No
Proteomics is used to identify prognostic markers after CPR. Additionally neurological
      outcome should be estimated by specific protein alterations and affections of pathways.
Proteomics is used to identify prognostic markers after CPR, i.e. altered proteins on a
      2G-gel. Additionally neurological outcome should be estimated by specific protein alterations
      and affections of pathways.
observational model: Cohort
time perspective: Prospective
measure: death at day 20
time frame: day 20
arm group label: dead
description: Patients dead until day 20 (primary outcome measure)
arm group label: survivors
description: patients alive after day 20 (primary outcome measure)
Serum and urine
study pop: 
sampling method: Probability Sample
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: No
last name: Jochen Hinkelbein, MD
role: Study Chair
affiliation: UK Köln
facility: 
country: Germany
responsible party type: Principal Investigator
investigator affiliation: Universitätsklinikum Köln
investigator full name: Jochen Hinkelbein
investigator title: Priv.-Doz. Dr. med.
mesh term: Heart Arrest